Acute Myeloid Leukaemia accounts for over 30% of all leukaemia diagnoses in Australia and has the worst survival rate. Current treatment involves high dose chemotherapy regimens and often bone marrow transplantation, however more than half of all adult AML patients will die of their disease. The disease is characterised by hundreds of different genetic mutations that leads to changes in the immature white blood cells - they grow rapidly, fail to develop into mature white blood cells and accumulate in bone marrow. This study will identify new proteins that are involved in causing AML which could lead to new drug targets for this cancer.
Finding the ‘disease-causing’ mutations and proteins in Acute Myeloid Leukaemia to develop new treatment strategies.